# EDGAR Filing Document

**Accession Number:** 0001114448
**File Stem:** 0001104659-26-004590
**Filing Date:** 2026-1
**Character Count:** 97487
**Document Hash:** 3f6b7496beea1b13f492d06fff554ca2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-004590.hdr.sgml**: 20260116

**ACCESSION NUMBER**: 0001104659-26-004590

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260116

**DATE AS OF CHANGE**: 20260116

**EFFECTIVENESS DATE**: 20260116

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVARTIS AG
- **CENTRAL INDEX KEY:** 0001114448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-258081
- **FILM NUMBER:** 26540082

**BUSINESS ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056
- **BUSINESS PHONE:** 01141613241111

**MAIL ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056

**As filed with the Securities and Exchange Commission on January 16, 2026**

**Registration No. 333-258081**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1**

**TO**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Novartis AG**

(Exact name of registrant as specified in its charter)

Switzerland N/A <br> (State or other jurisdiction of<br> incorporation or organization) (I.R.S. Employer<br> Identification No.)

**Lichtstrasse 35**

**CH-4056 Basel, Switzerland**

(Address of principal executive offices)

**Novartis Corporation Employee Share Purchase Plan for North American Employees**

(Full title of the plan)

**Karen L. Hale**

**Chief Legal & Compliance Officer**

**Novartis AG**

**Lichtstrasse 35**

**CH-4056 Basel, Switzerland**

(Name and address of agent for service)

**+41 61 324 1111**

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ⌧ Accelerated filer ◻ Non-accelerated filer ◻ Smaller reporting company ◻

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Post-Effective Amendment No. 1 (the "Post-Effective Amendment") to the Registration Statement on <u>Form S-8, File No. 333-258081</u> (the "Registration Statement") is filed by Novartis AG for the purpose of filing the Novartis Corporation Employee Share Purchase Plan for North American Employees, as Exhibit 99 to the Registration Statement and amending certain other sections hereto. No additional securities are being registered.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **INCORPORATION OF DOCUMENTS BY REFERENCE**

The following documents previously filed with or furnished to the Commission by Novartis AG (the "**Registrant**") are incorporated by reference herein and shall be deemed to be part hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) [Registrant's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on January 31, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1114448/000137036825000004/nvs-20241231.htm);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) our Reports on Form 6-K furnished to the SEC on [April 29, 2025](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000010/a250429-6k.htm) (only with respect to (i) the information under "R&D update — key developments from the first quarter" in Exhibit 99.1 thereto and (ii) Exhibit 99.2 thereto), [July 17, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1114448/000137036825000012/nvs-20250630.htm) (film number 251128805) (only with respect to (i) the information under "R&D update — key developments from the second quarter" in Exhibit 99.1 thereto and (ii) Exhibit 99.2 thereto), [July 17, 2025](https://www.sec.gov/Archives/edgar/data/1114448/000117184325004531/f6k_071725.htm) (film number 251130806) (only with respect to the first full paragraph of the Press Release included therein), [October 27, 2025](https://www.sec.gov/Archives/edgar/data/1114448/000117184325006660/f6k_102625.htm), [October 28, 2025](https://www.sec.gov/Archives/edgar/data/1114448/000111444825000003/a251028-6k.htm) (only with respect to (i) the information under "R&D update — key developments from the third quarter" in Exhibit 99.1 thereto and (ii) Exhibit 99.2 thereto) and [November 25, 2025](https://www.sec.gov/Archives/edgar/data/1114448/000117184325007547/f6k_112425.htm).

All documents filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 (the "**Exchange Act**") subsequent to the date hereof and prior to the filing of a post-effective amendment indicating that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date such reports are filed.

Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related prospectus to the extent that a statement contained herein or in any other subsequently filed document which is also incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Exhibit** |
| [4.1\*](tm262520d1_ex4-1.htm) | [Articles of Incorporation of Novartis AG, as amended March 7, 2025 (English translation)](tm262520d1_ex4-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000004/a25013120f-ex1_2.htm) | [Organizational Regulations of Novartis AG, effective January 1, 2025 (incorporated by reference to Exhibit 1.2 to Novartis AG's Annual Report on Form 20-F as filed with the Commission on January 31, 2025).](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000004/a25013120f-ex1_2.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm) | [Form of Second Amended and Restated Deposit Agreement among Novartis AG, JPMorgan Chase Bank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Receipts ("ADRs") issued thereunder, including the Form of ADR attached as Exhibit A thereto (incorporated by reference to Exhibit (a) to Novartis AG's registration statement on Form F-6 (File No. 333-198623) as filed with the Commission on December 16, 2022)](https://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm) | [Form of American Depositary Receipt (included as Exhibit A to Exhibit 4.3)](https://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm) |
| [23.1](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000004/a25013120f-ex15_1.htm) | [Consent of Independent Auditors (incorporated by reference to Exhibit 15.1 to Novartis AG's Annual Report on Form 20-F as filed with the Commission on January 31, 2025).](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000004/a25013120f-ex15_1.htm) |
| [24\*](#a_001) | [Powers of Attorney (included on signature pages)](#a_001) |
| [99\*](tm262520d1_ex99.htm) | [Novartis Corporation Employee Share Purchase Plan for North American Employees](tm262520d1_ex99.htm) |
| \* | Filed herewith |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. 333-258081) to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, Switzerland on January 16, 2026.

---

| | | |
|:---|:---|:---|
| **NOVARTIS AG** | **NOVARTIS AG** | **NOVARTIS AG** |
| By: | /s/ Harry Kirsch | /s/ Harry Kirsch |
|  | Name: | Harry Kirsch |
|  | Title: | Chief Financial Officer |
| By: | /s/ Karen L. Hale | /s/ Karen L. Hale |
|  | Name: | Karen L. Hale |
|  | Title: | Chief Legal & Compliance Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Harry Kirsch, Mukul Mehta, Karen L. Hale, Daniel Weiss, Laurent Sigismondi, and each of them (with full power to each of them to act alone), his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. 333-258081) has been signed by the following persons in the capacities indicated on January 16, 2026.

---

| | |
|:---|:---|
| **SIGNATURE** | **TITLE** |
| /s/ Vasant Narasimhan | Chief Executive Officer |
| Vasant Narasimhan, M.D. | (principal executive officer) |
| /s/ Harry Kirsch | Chief Financial Officer |
| Harry Kirsch | (principal financial and accounting officer) |
| /s/ Giovanni Caforio | Chair of the Board of Directors |
| Giovanni Caforio, M.D. |  |
| /s/ Simon Moroney | Vice-Chair of the Board of Directors |
| Simon Moroney, D.Phil. |  |
| /s/ Nancy C. Andrews | Director |
| Nancy C. Andrews, M.D., Ph.D. |  |
| /s/ Ton Buechner | Director |
| Ton Buechner |  |
| /s/ Patrice Bula | Director |
| Patrice Bula |  |
| /s/ Elizabeth Doherty | Director |
| Elizabeth Doherty |  |
| /s/ Bridgette Heller | Director |
| Bridgette Heller |  |
| /s/ Daniel Hochstrasser | Director |
| Daniel Hochstrasser |  |
| /s/ Frans van Houten | Director |
| Frans van Houten |  |
| /s/ Elizabeth McNally | Director |
| Elizabeth McNally, M.D., Ph.D. |  |
| /s/ Ana de Pro Gonzalo | Director |
| Ana de Pro Gonzalo |  |
| /s/ John D. Young | Director |
| John D. Young |  |

---

**AUTHORIZED REPRESENTATIVE**

Pursuant to the requirements of the Securities Act of 1933, the undersigned certifies that it is the duly authorized United States representative of the Registrant and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (File No. 333-258081) to be signed on its behalf by the undersigned, thereunto duly authorized, in East Hanover, New Jersey on January 16, 2026.

---

| |
|:---|
| /s/ Jaime Huertas |
| Jaime Huertas |

---

## Exhibit 4.1

**Exhibit 4.1**

![](tm262520d1_ex4-1img001.jpg)

---

| | |
|:---|:---|
| **2** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
| **Section 1** | Corporate Name, Registered Office, Purpose and Duration | 3 |
| **Section 2** | Share Capital | 3 |
| **Section 3** | Corporate Bodies | 5 |
|  | A. General Meeting of Shareholders | 5 |
|  | B. Board of Directors | 8 |
|  | C. Auditors | 11 |
| **Section 4** | Compensation of the Board of Directors and the Executive Committee | 11 |
| **Section 5** | Annual Financial Statements, Consolidated Financial Statements and Profit Allocation | 15 |
| **Section 6** | Publications and Place of Jurisdiction | 15 |

---

---

| | |
|:---|:---|
| **3** | Articles of Incorporation of Novartis AG |

---

---

| | |
|:---|:---|
| **Section 1** | **Corporate Name, Registered Office, Purpose and Duration** |
|  | Article 1 |
| Corporate name, Registered office | Under the Corporate name<br> Novartis AG<br> Novartis SA<br> Novartis Inc.<br> there exists a company limited by shares with its registered office in Basel. |
|  | Article 2 |

---

---

| | | |
|:---|:---|:---|
| Purpose | 1 | Purpose of the Company is to hold interests in enterprises in the area of health care or nutrition. The Company may also hold interests in enterprises in the areas of biology, chemistry, physics, information technology or related areas. |
|  | 2 | The Company may acquire, mortgage, liquidate or sell real estate and intellectual property rights in Switzerland or abroad. |
|  | 3 | In pursuing its purpose, the Company strives to create sustainable value. |
|  |  | Article 3 |
| Duration |  | The duration of the Company is unlimited. |

---

---

| | | |
|:---|:---|:---|
| **Section 2** |  | **Share Capital** |
|  |  | Article 4 |
| Share capital |  | The share capital of the Company is CHF 1 035 086 714.83, fully paid-in and divided into 2 112 421 867 registered shares. Each share has a nominal value of CHF 0.49. |
|  |  | Article 5 |
| Shareholders register and restrictions of registration, | 1 | The Company shall maintain a shareholders register showing the last names, first names, domicile, address and nationality (in the case of legal entities the registered office) of the holders or usufructuaries of registered shares. |
| Nominees | 2 | Upon request acquirers of registered shares are registered in the shareholders register as shareholders with the right to vote, provided that they declare explicitly to have acquired the registered shares in their own name and for their own account. Subject to the restrictions set forth in paragraph 6 of this article, no person or entity shall be registered with the right to vote for more than 2% of the registered share capital as set forth in the commercial register. This restriction of registration also applies to persons who hold some or all of their shares through nominees pursuant to this article. All of the foregoing is subject to Article 685d paragraph 3 of the Swiss Code of Obligations. |

---

---

| | |
|:---|:---|
| **4** | Articles of Incorporation of Novartis AG |

---

---

| | |
|:---|:---|
| 3 | The Board of Directors may register nominees with the right to vote in the share register to the extent of up to 0.5% of the registered share capital as set forth in the commercial register. Registered shares held by a nominee that exceed this limit may be registered in the shareholders register if the nominee discloses the names, addresses and the number of shares of the persons for whose account it holds 0.5% or more of the registered share capital as set forth in the commercial register. Nominees within the meaning of this provision are persons who do not explicitly declare in the request for registration to hold the shares for their own account and with whom the Board of Directors has entered into a corresponding agreement. |
| 4 | Corporate bodies and partnerships or other groups of persons or joint owners who are interrelated to one another through capital ownership, voting rights, uniform management or otherwise linked as well as individuals or corporate bodies and partnerships who act in concert to circumvent the regulations concerning the limitation of participation or the nominees (especially as syndicates), shall be treated as one single person or nominee within the meaning of paragraphs 2 and 3 of this article. |
| 5 | After hearing the registered shareholder or nominee, the Board of Directors may cancel registrations in the shareholders register with retroactive effect as of the date of registration if the registration was effected based on false information. The respective shareholder or nominee shall be informed immediately of the cancellation of the registration. |
| 6 | The Board of Directors shall specify the details and give the necessary orders concerning the adherence to the preceding regulations. In particular cases it may allow exemptions from the limitation for registration in the share register or the regulation concerning nominees. It may delegate its duties. |
| 7 | The limitation for registration in the share register provided for in this article shall also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights. |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 6 |
| Form of shares | 1 | Subject to paragraphs 2 and 4 of this article, the registered shares of the Company are issued as uncertificated securities (in terms of the Swiss Code of Obligations) and as book entry securities (in terms of the Book Entry Securities Act). |
|  | 2 | The Company may withdraw shares issued as book entry securities from the custodian system (Verwahrungssystem). |
|  | 3 | Provided that the shareholder is registered in the shareholders register, the shareholder may request from the Company a statement of his or her registered shares at any time. |

---

---

| | |
|:---|:---|
| **5** | Articles of Incorporation of Novartis AG |

---

---

| | |
|:---|:---|
| 4 | The shareholder has no right to the printing and delivery of certificates. The Company may, however, print and deliver certificates (individual share certificates, certificates or global certificates) for shares at any time. The Company may, with the consent of the shareholder, cancel issued certificates that are returned to the Company. |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 7 |
| Exercise of rights | 1 | The shares are not divisible. The Company accepts only one representative per share. |
|  | 2 | The right to vote and the other rights associated with a registered share may only be exercised vis-à-vis the Company by a shareholder, usufructuary or nominee who is registered in the share register. |
| **Section 3** |  | **Corporate Bodies** |
|  |  | **A. General Meeting of Shareholders** |
|  |  | Article 8 |
| Competence |  | The General Meeting of Shareholders is the supreme body of the Company. |
|  |  | Article 9 |
| General Meetings<br> a. Annual General Meeting |  | The Annual General Meeting of Shareholders shall be held each year within six months after the close of the financial year of the Company. |
|  |  | Article 10 |
| b. Extraordinary General <br> Meetings of Shareholders | 1 | Extraordinary General Meetings of Shareholders shall take place upon request of the Board of Directors or the Auditors. |
|  | 2 | Furthermore, Extraordinary General Meetings of Shareholders shall be convened upon resolution of a General Meeting of Shareholders or if it is required by one or more shareholders who are representing in the aggregate not less than 5% of the share capital and submit a petition signed by such shareholder or shareholders specifying the items for the agenda and the proposals. |
|  |  | Article 11 |
| Convening of General Meetings of Shareholders | 1 | General Meetings of Shareholders shall be convened by the Board of Directors at the latest twenty days before the date of the meeting. The meeting shall be convened by way of a notice appearing once in the Swiss Official Gazette of Commerce |
|  | 2 | The content of a notice of meeting is governed by the law. |

---

---

| | |
|:---|:---|
| **6** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 12 |
| Agenda | 1 | One or more shareholders whose combined shareholdings represent an aggregate nominal value of at least CHF 1 million may demand that an item be included in the agenda of a General Meeting of Shareholders. Such a demand must be made in writing at the latest forty-five days before the meeting and shall specify the items and the proposals of such a shareholder. If an explanatory statement is to be included in the notice of meeting, it must be submitted within the same period and formulated in a short, clear and concise manner. |
|  | 2 | No resolution shall be passed at a General Meeting of Shareholders on matters for which no proper notice was given. This provision shall not apply to proposals to convene an Extraordinary General Meeting of Shareholders or to initiate a special investigation. |
|  |  | Article 12a |
| Electronic Participation | 1 | The Board of Directors may foresee that shareholders who cannot be present at the venue of the General Meeting of Shareholders may exercise their rights through electronic means. |
|  | 2 | The Board of Directors may at any time until June 30, 2028 also order that the General Meeting of Shareholders be held electronically without a venue. |
|  |  | Article 13 |
| Presiding officer, Minutes, Vote counters | 1 | The General Meeting of Shareholders shall take place at the registered office of the Company, unless the Board of Directors decides otherwise. The Chair of the Board of Directors or in the Chair's absence a Vice-Chair or any other member of the Board of Directors designated by the Board of Directors shall take the chair. |
|  | 2 | The presiding officer shall appoint a secretary and the vote counters. The minutes shall be signed by the presiding officer and the secretary. |
|  |  | Article 14 |
| Proxies | 1 | The Board of Directors may issue regulations regarding the participation and the representation at the General Meeting of Shareholders and may allow electronic proxies without qualified signatures. |
|  | 2 | A shareholder can be represented by a legal representative or, by means of a written proxy, by a representative of choice. Furthermore, a shareholder may be represented by the Independent Proxy (in German: *Unabhängiger Stimmrechtsvertreter*). |
|  | 3 | The General Meeting of Shareholders shall elect the Independent Proxy for a term of office lasting until completion of the next Annual General Meeting of Shareholders. Re-election is possible. |
|  | 4 | If the Company does not have an Independent Proxy, the Board of Directors shall appoint the Independent Proxy for the next General Meeting of Shareholders. |

---

---

| | |
|:---|:---|
| **7** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 15 |
| Voting rights |  | Each share provides entitlement to one vote. |
|  |  | Article 16 |
| Resolutions, Elections | 1 | Unless the law requires otherwise, the General Meeting passes resolutions and elections with the absolute majority of the votes validly represented. |
|  | 2 | Resolutions and elections shall be taken either on a show of hands or by electronic voting, unless the General Meeting decides for, or the presiding officer orders, a secret ballot. |
|  | 3 | The presiding officer may at any time order to repeat an election or resolution taken on a show of hands with a secret ballot, if the presiding officer doubts the results of the vote. In this case, the preceding election or resolution taken on a show of hands is deemed not to have taken place. |
|  | 4 | If no election has taken place at the first ballot and if there is more than one candidate, the presiding officer shall order a second ballot in which the relative majority shall be decisive. |
|  |  | Article 17 |
| Powers of the General Meeting |  | The following powers shall be vested exclusively in the General Meeting of Shareholders: |

---

---

| | |
|:---|:---|
| of Shareholdersa) | To adopt and amend the Articles of Incorporation; |
| b) | To elect and remove the members of the Board of Directors, the Chair of the Board of Directors, the members of the Compensation Committee, the Independent Proxy and the Auditors; |
| c) | To approve the management report (if required), the consolidated financial statements and the report on non-financial matters; |
| d) | To approve the financial statements and to decide on the appropriation of available earnings shown on the balance sheet, in particular with regard to dividends (including any repayment of the statutory capital reserves and the approval of interim dividends and the interim financial statements required for such purpose); |
| e) | To approve the aggregate amounts of compensation of the Board of Directors and the Executive Committee in accordance with Article 29 of these Articles of Incorporation; |
| f) | To grant discharge to the members of the Board of Directors and to the members of the Executive Committee; |
| g) | To delist the shares of the Company; and |
| h) | To decide on matters that are reserved by law or by the Articles of Incorporation to the General Meeting of Shareholders. |

---

---

| | |
|:---|:---|
| **8** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  | Article 18 | Article 18 |
| Special quorum | The approval of at least two-thirds of the votes represented is required for resolutions of the General Meeting of Shareholders on: | The approval of at least two-thirds of the votes represented is required for resolutions of the General Meeting of Shareholders on: |
|  | a) | An alteration of the purpose of the Company; |
|  | b) | The consolidation of shares, unless the approval of all affected shareholders is required; |
|  | c) | An increase of the share capital out of equity, by contributions in kind or by way of set off against a receivable and the grant of special rights; |
|  | d) | A restriction or suspension of rights of option to subscribe; |
|  | e) | The introduction of a conditional capital or a capital band; |
|  | f) | An implementation of restrictions on the transfer of registered shares and the removal of such restrictions; |
|  | g) | The creation of shares with increased voting powers; |
|  | h) | The change of the currency of the share capital; |
|  | i) | The introduction of the deciding vote for the presiding officer at the General Meeting of Shareholders; |
|  | j) | A provision in the Articles of Incorporation allowing to hold the General Meeting of Shareholders abroad; |
|  | k) | The delisting of the shares of the Company; |
|  | l) | A change of location of the registered office of the Company; |
|  | m) | The introduction of an arbitration clause in the Articles of Incorporation; |
|  | n) | The merger, split or transformation of the Company under the Merger Act (subject to mandatory statutory provisions); and |
|  | o) | The dissolution of the Company. |

---

---

| | | |
|:---|:---|:---|
|  |  | **B. Board of Directors** |
|  |  | Article 19 |
| Number of Directors |  | The Board of Directors shall consist of a minimum of 8 and a maximum of 16 members. |
|  |  | Article 20 |
| Term of office | 1 | The members of the Board of Directors and the Chair of the Board of Directors shall be elected individually by the General Meeting of Shareholders for a term of office lasting until completion of the next Annual General Meeting of Shareholders. |
|  | 2 | Members whose term of office has ended may be immediately re-elected, subject to paragraph 3 hereinafter. |
|  | 3 | A member shall not serve on the Board for more than 12 years. The Board of Directors may, under certain circumstances and if deemed in the best interests of the Company, recommend exceptions to this rule to the General Meeting of Shareholders. |

---

---

| | |
|:---|:---|
| **9** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 21 |
| Organization | 1 | The Board of Directors constitutes itself in compliance with legal requirements and taking into consideration the resolutions of the General Meeting of Shareholders. It shall elect one or two Vice-Chairs. It shall appoint a secretary, who need not be a member of the Board of Directors. |
|  | 2 | If the office of the Chair of the Board of Directors is vacant, the Board of Directors shall appoint a new Chair from amongst its members for the remaining term of office. |
|  |  | Article 22 |
| Convening of meetings |  | The Chair shall convene meetings of the Board of Directors if and when the need arises or if a member so requires in writing. |
|  |  | Article 23 |
| Meetings, Resolutions | 1 | The organization of the meetings, including the quorum and the passing of resolutions, is regulated by the Board of Directors in the organizational regulations. |
|  | 2 | The presiding officer shall not have the deciding vote. |

---

Article 24 <br>Powers of the Board of Directors 1 The Board of Directors has in particular the following non-delegable and inalienable duties:

a) The
 ultimate direction of the Company's business and issuing of the necessary directives;

b) The
 determination of the organization of the Company;

c) The
 determination of the principles of accounting, financial controlling and financial planning;

d) The
 appointment and removal of the persons entrusted with the management and representation of
 the Company (including the CEO and the other members of the Executive Committee);

e) The
 ultimate supervision of the persons entrusted with the management of the Company, specifically
 in view of their compliance with the law, Articles of Incorporation, regulations and directives;

f) The
 preparation of the annual report, the compensation report and the report on non-financial
 matters in accordance with the provisions of the law and the Articles of Incorporation, as
 well as further reports which must be approved by the Board of Directors;

g) The
 preparations for the General Meeting of Shareholders and carrying out of the resolutions
 of the General Meeting of Shareholders;

h) The
 filing of a request for a moratorium and the notification to the court in the event of over-indebtedness;

---

| | |
|:---|:---|
| **10** | Articles of Incorporation of Novartis AG |

---

i) The
 adoption of resolutions concerning the implementation of changes in share capital to the
 extent that such power is vested in the Board of Directors, as well as resolutions concerning
 the confirmation of changes in share capital and respective amendments to the Articles of
 Incorporation; and

j) All further non-delegable and inalienable duties
 of the Board of Directors provided for by the law.

---

| | | |
|:---|:---|:---|
|  | 2.0 | In addition, the Board of Directors can pass resolutions with respect to all matters which are not reserved to the authority of the General Meeting of Shareholders by law or by these Articles of Incorporation. |
|  |  | Article 25 |
| Delegation of powers |  | The Board of Directors may, within the limits of the law and the Articles of Incorporation, delegate the management of the Company in whole or in part to one or several of its members (including to ad hoc or permanent committees of the Board of Directors) or to third persons (Executive Committee). |
|  |  | Article 26 |
| Signature power |  | The Board of Directors shall designate those of its members as well as those third persons who shall have legal signatory power for the Company, and shall further determine the manner in which such persons may sign on behalf of the Company. |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 27 |
| Organization and powers of the Compensation Committee | 1 | The Compensation Committee shall consist of a minimum of 3 and a maximum of 5 members of the Board of Directors. |
|  | 2 | The members of the Compensation Committee shall be elected individually by the General Meeting of Shareholders for a term of office lasting until completion of the next Annual General Meeting of Shareholders. Members of the Compensation Committee whose term of office has expired shall be immediately eligible for re-election. |
|  | 3 | If there are vacancies on the Compensation Committee, the Board of Directors shall appoint substitutes for the remaining term of office. |
|  | 4 | The Board of Directors shall elect a chair of the Compensation Committee. The Board of Directors shall, within the limits of the law and the Articles of Incorporation, define the organization of the Compensation Committee in regulations. |
|  | 5 | The Compensation Committee has the following powers: |

---

a) Develop
 a compensation strategy in line with the principles described in the Articles of Incorporation
 and submit it for approval to the Board of Directors;

b) Propose
 to the Board of Directors the principles and structure of the compensation plans;

---

| | |
|:---|:---|
| **11** | Articles of Incorporation of Novartis AG |

---

c) Support
 the Board of Directors in preparing the proposals to the General Meeting of Shareholders
 regarding the compensation of the members of the Board of Directors and the Executive Committee;

d) Submit
 the compensation report to the Board of Directors for approval;

e) Inform
 the Board of Directors about policies, programs and key decisions as well as comparisons
 of compensation levels at key competitors;

f) Regularly
 report to the Board of Directors on the decisions and deliberations of the Compensation Committee;

g) Assume
 other responsibilities assigned to it by law, the Articles of Incorporation or by the Board
 of Directors.

---

| | | |
|:---|:---|:---|
|  | 6.0 | The Board of Directors issues regulations to determine for which positions of the Board of Directors and of the Executive Committee the Compensation Committee shall submit proposals regarding compensation, and for which positions it shall determine the compensation in accordance with the Articles of Incorporation. |
|  |  | **C. Auditors** |
|  |  | Article 28 |
| Term, Powers and Duties |  | The Auditors, who shall be elected by the General Meeting of Shareholders each year, shall have the powers and duties vested in them by law. |

---

---

| | |
|:---|:---|
| **Section 4** | **Compensation of the Board of Directors and the Executive Committee** |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 29 |
| Approval of compensation by the General Meeting of | 1 | The General Meeting of Shareholders shall approve annually and separately the proposals of the Board of Directors in relation to the maximum aggregate amount of: |

---

---

| | | |
|:---|:---|:---|
| Shareholders | a) | Compensation of the Board of Directors for the period until the next Annual General Meeting of Shareholders; and |
|  | b) | Compensation of the Executive Committee paid, promised or granted for the following financial year. |
|  | The Board of Directors may submit for approval by the General Meeting of Shareholders additional proposals relating to the same or different periods. | The Board of Directors may submit for approval by the General Meeting of Shareholders additional proposals relating to the same or different periods. |

---

---

| | |
|:---|:---|
| **12** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  | 2.0 | If the General Meeting of Shareholders rejects the proposal of the Board of Directors for the total compensation of the Board of Directors and/or the Executive Committee, the decision on how to proceed shall reside with the Board of Directors. The options for the Board of Directors shall be to either convene an Extraordinary General Meeting to submit a new compensation proposal, or to determine the compensation for the corresponding period on an interim basis, subject to approval at the next Annual General Meeting of Shareholders. |
|  | 3.0 | Notwithstanding the preceding paragraphs, the Company or companies controlled by it may pay out compensation prior to approval by the General Meeting of Shareholders subject to subsequent approval by a General Meeting of Shareholders. |
|  | 4.0 | The Board of Directors shall submit the compensation report to an advisory vote of the General Meeting of Shareholders. |
|  |  | Article 30 |
| Additional amount |  | If the maximum aggregate amount of compensation already approved by the General Meeting of Shareholders is not sufficient to also cover the compensation of one or more members who become members of the Executive Committee during a compensation period for which the General Meeting of Shareholders has already approved the compensation of the Executive Committee, the Company or companies controlled by it shall be authorized to pay or grant to such member(s) an additional amount during the compensation period(s) already approved. The total additional amount for each relevant compensation period for which approval by the General Meeting of Shareholders has already been obtained shall not exceed (in full and not *pro rata temporis*) 40% of the aggregate amount of compensation of the Executive Committee last approved by the General Meeting of Shareholders per compensation period. |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 31 |
| General compensation principles | 1 | Compensation of the non-executive members of the Board of Directors comprises fixed compensation elements only. In particular, non-executive members of the Board of Directors shall receive no company contributions to any pension plan, no performance-related elements and no financial instruments (e.g. options). |
|  | 2 | Compensation of the members of the Executive Committee comprises fixed and variable compensation elements. Fixed compensation comprises the base salary and may comprise other compensation elements and benefits. Variable compensation may comprise short-term and long-term compensation elements. |

---

---

| | |
|:---|:---|
| **13** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  | 3 | Compensation (to non-executive members of the Board of Directors and to members of the Executive Committee) may be paid or granted in the form of cash, shares, other benefits or in kind. Compensation to members of the Executive Committee may also be paid or granted in the form of financial instruments or similar units. Compensation may be paid by the Company or companies controlled by it. The Board of Directors determines the valuation of each compensation element on the basis of the principles that apply to the establishment of the compensation report. |
|  |  | Article 32 |
| Variable compensation | 1 | The variable compensation paid or granted to the members of the Executive Committee in a certain year shall consist of compensation elements from short- and long-term compensation plans (as defined in this Article 32). |
|  | 2 | The short-term compensation plans are based on performance metrics that take into account the performance of the Novartis Group and/or parts thereof, and/or individual targets. Achievements are generally measured based on the one-year period to which the short-term compensation relates. The short-term compensation pay-outs shall be subject to caps that may be expressed as predetermined multipliers of the respective target levels. |
|  | 3 | The long-term compensation plans are based on performance metrics that take into account strategic objectives of the Novartis Group (such as financial, innovation, Shareholder return and/or other metrics). Achievements are generally measured based on a period of not less than three years. The long-term compensation pay-outs shall be subject to caps that may be expressed as predetermined multipliers of the respective target levels. |
|  | 4 | The Board of Directors or, to the extent delegated to it, the Compensation Committee determines performance metrics, target levels, and their achievement. |
|  | 5 | The Board of Directors or, to the extent delegated to it, the Compensation Committee determines grant, vesting, blocking, exercise and forfeiture conditions of the compensation; they may provide for continuation, acceleration or removal of vesting and exercise conditions, for payment or grant of compensation assuming target achievement or for forfeiture in the event of predefined events such as death, disability, retirement or termination of an employment or mandate agreement. |

---

---

| | |
|:---|:---|
| **14** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 33 |
| Agreements with Members of the Board of Directors and of the Executive Committee | 1 | The Company or companies controlled by it may enter into agreements with members of the Board of Directors relating to their compensation for a term not exceeding the term of office of the respective members of the Board of Directors. The Company or companies controlled by it may enter into contracts of employment with members of the Executive Committee for a fixed term not exceeding one year or for an indefinite period of time with a notice period not exceeding 12 months. |
|  | 2 | Contracts of employment with members of the Executive Committee may contain a prohibition of competition for the time after the end of employment if this is commercially justified. The overall consideration for such prohibition shall not exceed the average annual compensation for the three preceding business years. |
|  |  | Article 34 |
| Mandates outside of the Novartis Group | 1 | No member of the Board of Directors may hold more than 10 additional mandates in other companies, of which no more than 4 additional mandates shall be in other listed companies. Chairs of the board of directors of other listed companies count as two mandates. Each of these mandates shall be subject to approval by the Board of Directors. |
|  | 2 | No member of the Executive Committee may hold more than 6 additional mandates in other companies, of which no more than 2 additional mandates shall be in other listed companies. Each of these mandates shall be subject to approval by the Board of Directors. Members of the Executive Committee are not allowed to hold chairs of the board of directors of other listed companies. |
|  | 3 | The following mandates are not subject to these limitations: |
|  | a) | Mandates in companies which are controlled by the Company; and |
|  | b) | Mandates which a member of the Board of Directors or of the Executive Committee holds at the request of the Company or companies controlled by it. No member of the Board of Directors or of the Executive Committee shall hold more than 5 such mandates. |

---

---

| | |
|:---|:---|
| 4 | Mandates shall mean any membership in the board of directors, in the executive board or in the advisory board, or a comparable function under foreign law, in a company with an economic purpose. Mandates in different legal entities which are under joint control are deemed one mandate. |
| 5 | The Board of Directors may issue regulations that may determine additional restrictions, taking into account the position of the respective member. |

---

---

| | |
|:---|:---|
| **15** | Articles of Incorporation of Novartis AG |

---

---

| | | |
|:---|:---|:---|
|  |  | Article 35 |
| Loans |  | No loans or credits shall be granted to the members of the Board of Directors or the Executive Committee. |
| **Section 5** |  | **Annual Financial Statements, Consolidated Financial Statements and Profit Allocation** |
|  |  | Article 36 |
| Financial year |  | The Board of Directors shall prepare for each financial year as of 31 December an annual report consisting of financial statements with a management report if required and the consolidated financial statements. |
|  |  | Article 37 |
| Allocation of profit shown on the balance sheet, Reserves | 1 | The allocation of the profit shown on the balance sheet shall be determined by the General Meeting of Shareholders subject to the legal provisions. The Board of Directors shall submit to the General Meeting of Shareholders its proposals. |
|  | 2 | In addition to statutory reserves additional reserves may be accrued. |
|  | 3 | Dividends which have not been claimed within five years after the due date fall back to the Company and shall be allocated to the general reserves. |
| **Section 6** |  | **Publications and Place of Jurisdiction** |
|  |  | Article 38 |
| Publications | 1 | Notifications to shareholders and external communications of the Company shall be made in the Swiss Official Gazette of Commerce. The Board of Directors may designate additional publication organs. |
|  | 2 | Notices to shareholders may instead or in addition be sent (i) by regular mail to their addresses entered in the share register, (ii) by email or (iii) in any other form that the Board of Directors deems appropriate. |
|  |  | Article 39 |
| Place of jurisdiction |  | The exclusive place of jurisdiction for any disputes arising from or in connection with the shareholdership in the Company shall be at the registered office of the Company. |

---

## Ex-99

**Exhibit 99**

**Novartis Corporation**

**Employee Share Purchase Plan for North American Employees**

Adopted, as amended and restated, by the Novartis Corporation Board of Directors on December 18, 2025

Effective January 1, 2026

**Contents**

---

| | | |
|:---|:---|:---|
| NOVARTIS CORPORATION EMPLOYEE SHARE PURCHASE PLAN FOR NORTH AMERICAN EMPLOYEES | NOVARTIS CORPORATION EMPLOYEE SHARE PURCHASE PLAN FOR NORTH AMERICAN EMPLOYEES | 2.0 |
| ***1.*** | ***Purpose and Structure of the Plan*** | 2.0 |
| ***2.*** | ***Rules of the Plan*** | 2.0 |
| ***3.*** | ***Purchases of Shares – Shares subject to the Plan*** | 3.0 |
| ***4.*** | ***Plan Administrator*** | 3.0 |
| ***5.*** | ***Eligibility*** | 4.0 |
| ***6.*** | ***Participation Procedure*** | 5.0 |
| ***7.*** | ***Purchase and Delivery of Shares or Cash Settlement*** | 7.0 |
| ***8.*** | ***Shareholder's Rights*** | 8.0 |
| ***9.*** | ***Taxes, Social Security Contributions and Other Costs*** | 10.0 |
| ***10.*** | ***Cessation of Employment*** | 10.0 |
| ***11.*** | ***International Employees*** | 11.0 |
| ***12.*** | ***Corporate Events*** | 12.0 |
| ***13.*** | ***Participant Rights and Obligations*** | 12.0 |
| ***14.*** | ***Risks*** | 13.0 |
| ***15.*** | ***Board's Powers*** | 13.0 |
| ***16.*** | ***Administration and Regulations*** | 13.0 |
| ***17.*** | ***Notices*** | 13.0 |
| ***18.*** | ***Data Protection*** | 14.0 |
| ***19.*** | ***Amendment and Termination of the Plan*** | 14.0 |
| ***20.*** | ***Compliance with Law and Articles of Incorporation*** | 14.0 |
| ***21.*** | ***Applicable Law;Venue*** | 15.0 |
| ***22.*** | ***Language*** | 15.0 |
| ***23.*** | ***Severability*** | 15.0 |
| ***24.*** | ***Definitions and Interpretation*** | 15.0 |

---

**NOVARTIS CORPORATION EMPLOYEE SHARE PURCHASE PLAN FOR NORTH AMERICAN EMPLOYEES**

***1.***  ***<u>Purpose and Structure of the Plan</u>*** 

The purpose of the Plan is to enhance the alignment of the Participants in the Plan with the interests of the Company, Novartis AG ("Novartis"), and Novartis' shareholders, and to foster long term value creation through employee share ownership. Participants in the Plan benefit from discounted share purchase.

The Plan is intended to have two components: a Code Section 423 component ("423 Component") and a non-Code Section 423 component ("Non-423 Component"). The Company intends for the 423 Component to apply to US Participants and to qualify as an "employee stock purchase plan" under Section 423 of the United States Internal Revenue Code ("Code"). The provisions of the 423 Component, accordingly, will be construed so as to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Code Section 423. The Non-423 Component is intended to apply to Puerto Rican Participants and Canadian Participants and is not intended to qualify as an "employee stock purchase plan" under Code Section 423. However, except as otherwise provided herein, the Company intends to administer the Non-423 Component in substantially the same manner as it administers the 423 Component.

Pursuant to the Plan, the Committee may in its discretion, and consistent with the requirements of Code Section 423, as applicable, offer Eligible Employees the opportunity to participate in the Plan by submitting Enrollment Requests during Election Periods. The Committee sets out eligibility rules. By completing and submitting Enrollment Requests in accordance with the Plan and any related policies, the Participants may elect Contribution Amounts to invest in Shares of Novartis. The per pay period Contribution Amounts will be deducted from the Participants' net salary and collected by their Employing Group Companies during the four Offer Periods per year. Upon the expiry of an Offer Period after each quarter the Total Contribution Amounts will be considered to purchase Shares for the Participants at a discount of 15% of the Shares' Market Value.

The Company may engage third party Plan Administrators to support with the management and technical execution of the Plan.

The Plan will be communicated to all Eligible Employees in such form as the Committee shall determine from time to time. Further communication and interaction regarding the Plan will be done via the Plan Administrator's online interface.

***2.***  ***<u>Rules of the Plan</u>*** 

2.1 <u>Rules</u> 

The following Rules govern the Plan.

2.2 <u>Schedules to the Plan</u> 

The Committee may establish Schedules to the Rules as it considers necessary or appropriate. Such Schedules may be included in the Plan in such a way that they create special rules applicable to certain Eligible Employees or categories of Eligible Employees and/or to constitute sub-plans to the Plan for Eligible Employees inside and outside the United States.

2.3 <u>Policies etc.</u> 

Participation in the Plan shall be subject to all applicable policies, procedures and guidelines adopted by the Committee from time to time.

***3.***  ***<u>Purchases of Shares – Shares subject to the Plan</u>*** 

(a) Subject
 to Rule 12.2, the aggregate number of Shares made subject to Purchase under this Plan may
 not exceed 14,000,000.

(b) Such
 Shares shall be deemed to have been used in payment of Purchases whether they are actually
 delivered or the market value equivalent of such Shares is paid in cash. In the event any
 Purchase of Shares is surrendered or terminated, or expires or is forfeited, the number of
 Shares no longer subject thereto shall thereupon be released and shall thereafter be available
 for new Purchases under this Plan.

(c) Shares
 comprising Purchases under this Plan or delivered by the Company in settlement of Purchases
 under this Plan may be derived from authorized and unissued Shares or from Shares held
 in the treasury of the Company or held by another member of the Group or may be purchased
 on the open market or by private purchase.

(d) In
 accordance with Code Section 423(b)(2), the Plan will be subject to approval by the
 stockholders of the Company within twelve (12) months after the date the Plan is adopted
 by the Board.

***4.***  ***<u>Plan Administrator</u>*** 

The Company, acting on behalf of all Participating Group Companies, will engage Plan Administrators for the management and technical execution of the Plan.

The management and technical execution of the Plan will be enabled by the Plan Administrators for the benefit of the Participants via their online interfaces based on a digital platform. Therefore, an Eligible Employee may also enter into an agreement with the respective Plan Administrator in order to become a Participant. By accessing and using this online platform, Eligible Employees accept the terms and conditions applicable to it, unless local law requires another form of acceptance, in which case an appropriate process for acceptance will be implemented.

The management and technical execution of the Plan by the Plan Administrators will include providing personal securities accounts for Participants with regard to the Participants' Shares under the Plan.

If the Company's contract with the Plan Administrator for management and technical execution of the Plan ends in circumstances where the Plan continues, the Company will make arrangements for appropriate services to be provided by another Plan Administrator that the Company shall instruct at its sole discretion. In such circumstances, each Participant must give all notices and take all steps necessary to end the existing agreements with the old Plan Administrator and appoint a new Plan Administrator.

The procedures specified above may be altered and other procedures may be established by the Committee.

***5.***  ***<u>Eligibility</u>*** 

5.1 <u>Eligibility for Participation in the Plan</u> 

Eligible Employees are granted the opportunity to participate in the Plan as soon as administratively practicable after they become Eligible Employees.

For the avoidance of doubt, third-party associates (i.e. contractors, consultants and other non-employee categories) shall not be eligible to participate in the Plan. In addition, such individuals shall not be eligible even if reclassified by a court or administrative agency. Additional or diverging conditions with respect to the Non-423 Component may be set forth in any applicable Schedules.

Notwithstanding the foregoing, an employee's status as Eligible Employee shall, subject to the applicable requirements of Code Section 423, remain entirely at the discretion of the Committee while it is bound to respect equal treatment and meet non-discriminatory principles. In addition, subject to the applicable requirements of Code Section 423, the Committee may also exclude certain employees, employee groups, countries and/or Group Companies completely from the Plan's program.

5.2 <u>No Public Offer</u> 

For the avoidance of doubt, the Plan shall not be regarded as a public offer of securities but is strictly limited to Eligible Employees of the Participating Group Companies.

5.3 <u>Insider Restrictions</u> 

An Eligible Employee subject to Insider Restrictions may be limited to participate in the Plan. For the avoidance of doubt and without limiting the generality of the foregoing, Eligible Employees must at all times fully comply with the Global Novartis Insider Policy; in particular, Eligible Employees who have knowledge of any Material Non-Public Information (as defined in the Global Novartis Insider Policy) may not make any decision to participate in the Plan, make any decision to increase or decrease their participation in the Plan, sell any Shares acquired under the Plan, or take any similar decisions under or in connection with the Plan; further, Continuing Insiders (as defined in the Global Novartis Insider Policy) must at all times comply with the Quiet Periods (as defined in the Global Novartis Insider Policy) and obtain Trade Approvals (as defined in the Global Novartis Insider Policy) when taking any relevant decision under or in connection with this Plan.

If any Participant purchases Shares in violation of the Insider Restrictions, the Participant shall be required to return such purchased Shares to the Company and upon such return the Participant will be refunded any Contribution Amounts used to purchase such Shares. The Participant will forfeit any discount associated with such purchased Shares.

Any Eligible Employee who is not certain as to whether or not the Insider Restrictions are applicable to him or her shall consult the Global Novartis Insider Policy or contact the respective Novartis insider support for clarification.

5.4 <u>Voluntary Participation and Acceptance</u> 

Each Eligible Employee shall voluntarily decide to participate in the Plan by accepting the Rules via the Plan Administrator's online interface, unless local law requires another form of acceptance, in which case an appropriate process for acceptance will be implemented.

By accepting any securities under this Plan, Canadian Participants subject to the provincial and/or federal laws of Canada shall be deemed to represent and warrant to the Company that such Canadian Participant's participation in the trade and acceptance of such securities is voluntary and that such Participant has not been induced to participate by expectation of engagement, appointment, employment or continued engagement, appointment or employment, as applicable.

***6.***  ***<u>Participation Procedure</u>*** 

6.1 <u>Discount</u> 

Under the Plan, Eligible Employees are offered to buy Shares with a discount of 15% on the Shares' Market Value and may become Participants to benefit from the discount.

6.2 <u>Election Period</u> 

Each Eligible Employee can submit an Enrollment Request for the purchase of Shares under the Plan during fixed Election Periods. An individual who becomes an Eligible Employee under this Plan may in accordance with procedures established by the Committee submit an Enrollment Request during the first available Election Period that occurs after the date on which the individual becomes an Eligible Employee. Enrollment Requests may be submitted in a predetermined timeframe between an opening date and a closing date prior to the respective Offer Period. The timeframe of the Election Periods may be updated by the Committee from time to time.

Any Enrollment Request submitted outside of the relevant Election Period will be disregarded.

6.3 <u>Enrollment Request</u> 

Each Eligible Employee wishing to submit an Enrollment Request may do so by completing an Enrollment form and all required brokerage account opening forms, which are made available by the Company via the Plan Administrator's online interface. As long as the Eligible Employee has not provided the necessary documents to open a brokerage account, he or she will not be able to participate in the Plan.

The Eligible Employee shall indicate on the Enrollment form the Contribution Amount per pay-period, in the currency of his or her Base Salary or, if available, as a percentage thereof, that he or she wishes to invest in Shares.

A submitted Enrollment Request shall be valid for the relevant Offer Period as well as subsequent Offer Periods, unless and until modified or revoked during the respective Election Period by the Participant.

After expiry of the respective Election Period, the Enrollment Request is final, meaning that modifications and revocations to the Enrollment Request for the relevant Offer Period by the Participant are not possible anymore. The Enrollment Request may only be modified or revoked in the following Election Period for the respective Offer Period(s).

Enrollment Requests may, at any time, be modified or refused by the Plan Administrator to be compliant with the Plan as well as applicable local laws and regulations.

By submitting an Enrollment Request, the Participant shall be deemed to accept and agree to be bound by these Rules, including any applicable Schedule(s) and the applicable terms and conditions of the Plan Administrator, in each case, as such rules, supplement(s) and terms and conditions may be modified from time to time.

6.4 <u>Contribution Amount</u> 

The Participant's Total Contribution Amount shall be considered for the purchase of Shares.

The annual Contribution Amount of each Participant is limited to a maximum of 15% of his or her Base Salary per calendar year or USD 21,250 (respectively the local currency equivalent) per calendar year, whichever is lower. Any limits to the maximum Contribution Amount in an Offer Period shall be established by the Committee and shall be stated in the Plan Administrator's online interface.

The relevant minimum Contribution Amount for each country shall be established by the Committee and shall be stated in the Plan Administrator's online interface.

The local currency equivalent will be calculated based on an average exchange rate determined by the Committee in its discretion for the month prior to the first Election Period of each year and shall be fixed for that calendar year. Notwithstanding the foregoing, the Committee may decide in its discretion to apply a deviating exchange rate, which will then be communicated to the Participants in due course. Further details may be stipulated by the Committee.

In any case, the Market Value of the purchased Shares for each Participant may not exceed USD 25,000 (respectively the local currency equivalent) for any one calendar year.

6.5 <u>Period for Collection of Contribution Amount</u> 

The Contribution Amount shall be deducted from the Participant's net Base Salary that is payable during the Offer Period(s). The Plan will be operated on a quarterly basis, while each Offer Period starts at the beginning of a three-month period and ends at the closing date of a three-month period. The initial Offer Period is expected to start on January 1, 2022 and end on March 31, 2022, with a corresponding initial Election Period as established by the Committee expected to occur during the fourth quarter of 2021. Diverging periods and dates may be established by the Committee.

6.6 <u>Collection of Contribution Amount</u> 

The Contribution Amount shall be collected through payroll deductions made during the respective Offer Period(s) from the Participants' net Base Salary via the Employing Group Company's payroll, insofar as this is possible and legally permitted (for example limits of seizure, minimum wages and any restrictions under collective agreements will be obeyed). For this purpose, by submitting the Enrollment Request the Participant expressly authorizes and requests that the Employing Group Company withholds from his or her payroll the Contribution Amount.

If the Contribution Amount is not covered by the net Base Salary amount available for deduction on the Participant's payroll, the Contribution Amount shall be reduced to the amount deductible from such Participant's payroll, unless other procedures are in place with the Participant's payroll.

A Participant who ceases to be entitled to receive a Base Salary will automatically stop making contributions to the Plan.

Subject to any limits to the maximum Contribution Amount in an Offer Period that may be established by the Committee, a Participant who reaches the maximum annual Contribution Amount in less than four Offer Periods will automatically stop making contributions to the Plan for that calendar year.

Contribution Amounts collected in a currency other than USD will be converted to USD on the date of purchase based on the exchange rate as determined by the Committee or its delegate in its discretion. The Committee or its delegate may amend the exchange rate from time to time prior to any Election Period, which will then be communicated to the Participants in due course. Further details may be stipulated by the Committee or its delegate pursuant to policies, procedures or guidelines for administering this Plan.

6.7 <u>Recordkeeping for Collected Contribution Amount</u> 

Appropriate accounting records shall be maintained by the Employing Group Company to reflect the deducted Contribution Amounts under the Plan for the purchase of Shares by each Participant. Unless otherwise required by applicable law, the Participant's deducted Contribution Amounts will not be kept separate from the general funds of the Employing Group Company.

***7.***  ***<u>Purchase and Delivery of Shares or Cash Settlement</u>*** 

7.1 <u>Share Purchase</u> 

The Total Contribution Amounts collected during an Offer Period shall in accordance with procedures established by the Committee be considered to purchase Shares on the Purchase Date.

The price per Share will be equal to the Market Value of the Share minus a 15% discount, the Purchase Price.

The number of Shares purchased shall be equal to the Total Contribution Amounts divided by the Purchase Price; if any, resulting Share fractions (up to three digits to the right of the decimal) are permitted, if at least one whole Share is purchased. In case the Total Contribution Amounts are not sufficient to purchase one whole Share, the Total Contribution Amounts shall be carried forward and considered to purchase Share(s) after the following Offering Period or refunded as soon as administratively practicable after the Purchase Date if the Participant decides against future Share purchases.

7.2 <u>Delivery of Shares</u> 

All Shares purchased by the Participant under the Plan shall be transferred to and registered in his or her personal securities account established by the Plan Administrators, except for the fractional Share in which the Participant shall hold only a beneficial interest. For the sake of clarity, prior to the delivery of the Shares to the account, a Participant has no rights relating to the Shares or fractional Share.

Purchased Shares (including fractional Share) shall be visible on the Plan Administrator's online interface in due course and credited to his or her account as promptly as practicable after the purchase.

7.3 <u>Settlement in Cash</u> 

Irrespective of the provisions above, the Company reserves the right to pay or procure to be paid in local currency to the Participant a sum equal to the value at purchase of the number of Shares that would otherwise have been delivered to the Participant.

Any cash compensation will be paid via payroll to the Participant net of applicable tax and social security contributions due by the Participant, if any.

The Company cannot unilaterally decide to pay to a Canadian Participant a sum of cash equal to the value at purchase of the number of Shares that would otherwise have been delivered to the Participant. Any such cash payment to a Canadian Participant shall be subject to the Canadian Participant's consent.

***8.***  ***<u>Shareholder's Rights</u>*** 

8.1 <u>Shares under the Plan</u> 

Shares acquired under the Plan are registered Shares of Novartis.

8.2 <u>Statutory Rights</u> 

Each Participant shall have full statutory shareholder's rights with respect to his or her Share(s) as from the date of recording in the share register of Novartis in the name of the Participant. Each Share shall entitle the holder to one vote at meetings of Novartis' shareholders.

Fractional Shares do not grant any corresponding shareholder's rights. However, a fractional Share shall entitle the holder to a corresponding pro rata dividend.

8.3 <u>Dividends</u> 

Each Participant is entitled to, if any, dividends for his or her Share(s) and to fractional dividends for his or her fractional Share. The amount of dividends allocated to (fractional) Share(s) held by a Participant under this Plan shall be automatically reinvested in additional Shares and/or an additional fractional Share, unless a Participant elects in accordance with procedures established by the Plan Administrator to receive such dividends in cash. The Share(s) shall be transferred to and registered on behalf of the Participant in the personal securities account established by the Plan Administrator, except for the allocated fractional Share in which the Participant shall hold only a beneficial interest.

Dividends shall be reinvested on the dividend payment date or as soon as administratively practicable thereafter.

Dividends reinvested as described above will be considered for tax purposes and may create a liability for the payment of tax without providing immediate cash to pay this tax when it becomes due. The amount of dividends less commissions, transaction fees, taxes and levies as applicable will be reinvested in (fractional) Share(s).

The Board may in its discretion decide whether dividends are paid out in cash to the Participant and will not automatically be reinvested in additional Shares or fractional Share.

8.4 <u>Transfer or Sale of Shares</u> 

After the Purchase Date, each Participant may transfer some or all of his or her Share(s) from his or her securities account with the Plan Administrator to another private securities account, subject to applicable laws. Only whole numbers of Shares may be transferred. In this event any such transfer shall be deemed a simultaneous direction to sell his or her fractional Share.

After the Purchase Date, each Participant may alternatively sell some or all of his or her Share(s) including a fractional Share directly from his or her securities account with the Plan Administrator. He or she may also direct the Plan Administrator to sell his or her fractional Share, provided that the proceeds of such sale do not fall below the arising transaction costs, if any.

Due to the sale of the Share(s) as well as the fractional Share, the Participant shall receive the sale proceeds less the arising transaction costs, if any.

Sales of Shares shall only be made in compliance with the Insider Restrictions. For the avoidance of doubt and without limiting the generality of the foregoing, Eligible Employees must at all times fully comply with the Global Novartis Insider Policy; in particular, Eligible Employees who have knowledge of any Material Non-Public Information (as defined in the Global Novartis Insider Policy) may not sell any Shares acquired under the Plan; further, Continuing Insiders (as defined in the Global Novartis Insider Policy) must at all times comply with the Quiet Periods (as defined in the Global Novartis Insider Policy) and obtain a Trade Approval (as defined in the Global Novartis Insider Policy) when selling Shares acquired under the Plan. Compliance with the Insider Restrictions shall be the responsibility of the Participant. By submitting a direction to sell Shares, the Participant shall be deemed to certify to the Company and the Plan Administrator that he or she is not in violation of the Insider Restrictions.

8.5 <u>No Transferability of Contribution Amount or any Rights under the Plan</u> 

Contribution Amounts and any rights to acquire Shares under the Plan may not be assigned, alienated, pledged, attached, sold or otherwise disposed of in any way (other than by will, the laws of descent and corresponding distribution) by the Participant. In addition, Contribution Amounts and any rights to acquire Shares may not be assigned pursuant to a "domestic relations order" (as that term is defined in Code Section 414(p)(1)(B)), or any corresponding provisions under Canadian or Puerto Rico law.

***9.***  ***<u>Taxes, Social Security Contributions and Other Costs</u>*** 

9.1 <u>Tax and Social Security Regime</u> 

The tax and social security rules that apply to participation in the Plan differ depending on circumstances of the Participant, country of the Employing Group Company or country of residence. Both, the Participant and his or her Employing Group Company, may be subject to reporting and/or withholding/remittance requirements regarding the purchase of Share(s) under the Plan. The Participant accepts responsibility for compliance with his or her reporting and payment obligations, including his or her tax and social security obligations. It shall be the responsibility of each Participant to learn about the applicable tax and social security regime.

9.2 <u>Payment of Taxes and Social Security Contributions</u> 

If the Company and/or a Participating Group Company must pay income tax, social security contributions or any other type of duties on behalf of a Participant, where such duties are permitted and/or required by applicable laws or regulations to be deducted from the Participant's net pay, any Employing Group Company shall withhold such amount from the current and/or subsequent payrolls and make such arrangements as is considered necessary for such a deduction.

If the available amounts of net pay are not sufficient, the Participant shall be obliged to forward a payment in the appropriate amount to his or her Employing Group Company to cover the amount of duties.

9.3 <u>Other Costs</u> 

All costs relating to the administration and provision of personal securities accounts established by the Plan Administrators and the delivery of (fractional) Share(s) will be borne by the Company.

All costs, if any, arising in connection with the subsequent sale and transfer of (fractional) Share(s) under the Plan shall be borne by the Participants. The Company may in its discretion decide to also bear these costs.

9.4 <u>Sell-to-cover and Withhold-to-Cover</u> 

At the Committee's or its delegate's discretion, a number of Shares purchased under the Plan may be sold (Sell-to-Cover) or withheld (Withhold-to-Cover) in order to settle any type of duties. For this purpose, the Participant expressly authorizes the Plan Administrator, the Employing Group Company and the Company to sell or withhold Shares in an amount that is necessary to cover these duties.

***10.***  ***<u>Cessation of Employment</u>*** 

10.1 <u>Loss of Eligibility</u> 

Subject to Rule 10.3 below, if an Eligible Employee or Participant ceases employment for any reason, he or she loses eligibility to participate in the Plan with effect as of the Cessation of Employment.

10.2 <u>Void Enrollment Request</u> 

Upon Cessation of Employment, the Participant's Enrollment Request during an ongoing Election Period shall be deemed void with immediate effect.

10.3 <u>Refund of Contribution Amount</u> 

In accordance with procedures established by the Committee, in case a Participant's employment ceases prior to the upcoming Purchase Date, any Contribution Amount already deducted from the Participant's Base Salary but not yet used to purchase Shares shall be refunded to the Participant in cash as soon as administratively practicable after such Cessation of Employment. The Participant is not entitled to any compensation for the Share purchase discount or interest and the Participant waives, and shall have no entitlement to, any damages or other compensation whatsoever arising from, in lieu of, or related to any Shares which would have been purchased after the Cessation of Employment, including but not limited to damages in lieu of reasonable notice at common/civil law.

10.4 <u>Address and Contact Information</u> 

A Participant who ceases employment shall be obliged to keep his or her address and other contact information updated in the Plan Administrator's online interface for a minimum of two years following the Purchase Date.

***11.***  ***<u>International Employees</u>*** 

11.1 <u>International Assignees</u> 

If a Participant is assigned to work in another country based on his or her ongoing local employment contract with a Group Company, he or she shall continue to participate in the Plan as he or she would if he or she remained in the home country. Any taxable benefit from the purchase of Shares will be tax equalized with respect to the home country.

11.2 <u>International Transferees</u> 

If a Participant is transferred to work in another country outside of North America on local terms and conditions pursuant to a local employment contract with a Group Company, in accordance with procedures established by the Committee he or she shall be deemed to have withdrawn from further participation in the Plan, i.e. any Enrollment Request during an ongoing Election Period shall be deemed void with immediate effect, in case the Participant is transferred prior to the upcoming Purchase Date, any Contribution Amount already deducted from the Participant's net Base Salary, but not yet used to purchase Shares will be refunded to the Participant in cash as soon as administratively practicable following the transfer.

The transferred employee may be eligible to participate in the Novartis AG Employee Share Purchase Plan, as applicable, based on his or her local employment with a Group Company.

***12.***  ***<u>Corporate Events</u>*** 

12.1 <u>Change of Control</u> 

In the event of a Change of Control, the surviving, continuing, successor, or purchasing entity or parent entity thereof, as the case may be, may assume the Company's rights and obligations under the Plan or offer economically equivalent shares. If the acquiring entity elects not to assume the Company's rights and obligations under the Plan or to offer own shares, the Board may determine, in its sole discretion, to terminate the Plan and refund all unused Contribution Amounts.

Notwithstanding the preceding paragraph, the Board may in its discretion with no obligation to do so, define other consequences of a Change of Control.

12.2 <u>Demerger, Variations of Share Capital and other Corporate Events</u> 

If the Company was affected by any variation of share capital, rights issue, sub-division, consolidation or reduction of share capital, demerger, distribution (other than an ordinary dividend), liquidation or other event (other than a Change of Control) the Board may in its discretion adjust the Plan, including but not limited to, requiring some or all Shares to be sold or transferred. However, Participants shall not be entitled to any such adjustments.

***13.***  ***<u>Participant Rights and Obligations</u>*** 

The rights and obligations of a Participant under the terms of his or her office, employment or contract are not affected by becoming a Participant. These Rules do not form part of, and will not be incorporated into, any contract between a Participant and any Group Company.

A Participant does not have any right to continued employment with any of the Group Companies as a result of participating in the Plan, nor is he or she entitled to any compensation or damages if any benefit under the Plan is reduced or cancelled as a result of applying the Rules. For greater certainty, a Participant shall have no claim to or in respect of any Share(s) which may have or would have been delivered to the Participant after the Cessation of Employment and had due notice of termination of employment been given nor shall the Participant have any entitlement to damages or other compensation on any claim for wrongful termination or dismissal in respect of any Share(s) or loss of profit or opportunity with respect to any Share(s) which may have or would have been delivered to the Participant after the Cessation of Employment if such wrongful termination or dismissal had not occurred or if due notice of termination had been given.

Nothing in the Plan confers any benefit, right or expectation on a person who is not an Eligible Employee or a Participant.

The Plan is discretionary and is not part of any employment contract with the Employing Group Company or with any other Group Company and the Shares do not form an integral part of the Participant's compensation from employment, if applicable. Neither does the Plan create any employment contract between the Eligible Employee or Participant and the Company or any other Group Company, nor does the Plan give rise to a claim or legal entitlement to compensation for the Eligible Employee or Participant.

For the avoidance of doubt, benefits under the Plan are not pensionable under the Pension Plan for Salaried Employees of Novartis Corporation, the Novartis Corporation Investment Savings Plan, or any other qualified or nonqualified retirement plan, and such benefits do not count in relation to the calculation of benefit under programs such as life cover, income protection or continuation, medical or such other benefits as the Committee may determine.

***14.***  ***<u>Risks</u>*** 

Neither the Board, the Committee, the Company nor any Participating Group Company shall take any responsibility whatsoever for the general market development and performance of the prices of Shares. In particular, there is no guarantee that a Participant who has purchased Share(s) under the Plan will obtain an economic benefit as the prices of shares purchased under the Plan fluctuate and can also decrease. The Participant is expected to have reviewed the prospectus associated with the Plan. The Participant shall thus alone carry the risk connected to share acquisition, e.g. share price volatility and exchange rate fluctuations.

Subject to the requirements of applicable laws or regulations, neither the Company nor any Group Company shall accept responsibility for the fact that duties are withheld, or that the Participant might be obliged to pay duties, e.g. tax on capital gains or income taxes.

***15.***  ***<u>Board's Powers</u>*** 

Beyond the rights of modification as stipulated above the Plan may be changed or cancelled by the Board in its absolute discretion. Any future benefits under the Plan may therefore be changed or cancelled at any time.

The exercise of any power or discretion, including refraining from exercise, of the Board concerning the Plan is absolute and unlimited and may be reasonably exercised at any time, subject always to the principle of good faith. When the Board exercises any of its powers or discretions in a way that will impact a Participant, the Board may inform the relevant Participant in such manner as the Board shall determine.

Any decision of the Board in connection with the Plan, the interpretation of the Plan and any related documents and in connection with any dispute relating to the Plan will be final and binding.

***16.***  ***<u>Administration and Regulations</u>*** 

The Plan shall be administered by the Committee.

The Committee may make and vary policies, procedures and guidelines for the administration and operation of the Plan, and may in its discretion delegate administrative authority as it determines appropriate.

***17.***  ***<u>Notices</u>*** 

Any notice or other communication under or in connection with the Plan may be given by the Company or Participating Group Company to an Eligible Employee or Participant by electronic mail or other electronic means (including the internet or the intranet) or by post addressed to the address last known to the Company (including any address supplied by the relevant Participating Group Company) or sent through the Company's internal postal service. Participants accept the risk of failure to receive notice or other communications if they self-block notices from the Company, any Participating Group Company, or any Plan Administrator.

***18.***  ***<u>Data Protection</u>*** 

For the purpose of the administration of the Plan, the Company and any other Group Company and any of their advisers or agents may, in accordance with applicable data protection laws, store, process, transfer and use personal data of Participants, also involving third parties employed or engaged to administer or to assist with the administration and implementation of the Plan. The expectation is that the data to be processed to administer the Plan will originate from Canada, Puerto Rico and the United States.

The Company and any other Group Company, whether data controllers or data processors, implemented and maintain adequate legal instruments as well as technical and organizational measures to comply with applicable data protection laws and company regulations.

All plan administrators, if any, are carefully selected and must comply with all applicable data protection standards and technology.

***19.***  ***<u>Amendment and Termination of the Plan</u>*** 

The Board may at any time change the Plan (including amending or adding Schedules to the Plan) in any way. Changes may affect benefits already granted provided always that, unless required by law, no such change may be made which is to the material disadvantage of a Participant without that Participant's prior electronic consent. The Board shall give notice of any changes to any Participant. The Board may terminate the Plan at any time. Termination will not affect the number of purchased Shares.

***20.***  ***<u>Compliance with Law and Articles of Incorporation</u>*** 

20.1 <u>Compliance with Law</u> 

The Plan is subject to all applicable laws and the Company's Articles. If such law or the Articles require, the terms of any provision of the Plan shall be interpreted and/or amended and applied to the extent required to comply fully with such law or the Articles.

20.2 <u>Swiss Law with Respect to the Compensation of certain Executives of Listed Companies</u> 

The Plan, in particular, is subject to any mandatory provisions of Swiss law pertaining to compensation of governing bodies derived from article 95 paragraph 3 of the Swiss Federal Constitution and the related implementing legislation (**VegüV** or later implementing Federal law). Any interpretation and/or amendment necessary in respect of any provision of the Plan as a result of applicable law and/or the Articles (whether currently in force or in the future) to the detriment of the Participant shall not give rise to any claims by or other rights whatsoever of the Participant. This applies, in particular, if the annual general meeting of the Company does not approve the compensation of the Participant which is subject to approval under the VegüV or later implemented Swiss Federal law.

20.3 <u>US Code Sections 409A and 457A</u> 

It is intended that all amounts to be paid or all Shares to be transferred in connection with the Plan will be either exempt from or in compliance with Section 409A of the U.S. Internal Revenue Code ("Code Section 409A") and Section 457A of the U.S. Internal Revenue Code ("Code Section 457A"), each including the Treasury Regulations and other requirements published in this regard, such that the Participant will not be liable for payment of additional taxes, penalties or interest pursuant to Code Section 409A or Code Section 457A. The Rules are to be construed and interpreted in such a way that such additional taxes, penalties or interest pursuant to Code Section 409A and Code Section 457A are not incurred, and the intended advantage to the Participant is preserved (to the greatest possible extent).

***21.***  ***<u>Applicable Law; Venue</u>*** 

The Plan is governed by and construed in accordance with the laws of the State of New Jersey, unless applicable law requires otherwise, under express exclusion of any provisions of conflict of laws. Any claims under this Plan shall be brought in the state or federal courts in the State of New Jersey, unless applicable law requires otherwise.

The Committee has the discretionary authority to resolve conclusively all questions of fact or interpretation concerning the Plan and has the authority to resolve any dispute of any kind that arises under or in connection with the Plan.

***22.***  ***<u>Language</u>*** 

The authoritative Rules are in English. Any version of the Rules in another language is purely a convenience translation. In the event of questions of interpretation or deviations between the English version and the translated Rules, the English version of the Rules shall be exclusively valid.

For the avoidance of any doubt, it is the express wish of the Company, Novartis, the Committee and the Participants that the Plan and all related documents be drafted in English. *La Compagnie, Novartis, le Comité et les Participants conviennent et exigent que le Plan ainsi que tous les documents qui s'y rattachent soient rédigés en langue Anglaise.*

***23.***  ***<u>Severability</u>*** 

Whenever possible, each provision of the Rules shall be interpreted in such a manner as to be effective and enforceable under the applicable law. However, each provision of the Rules is intended to be severable and if any provision is determined by a court of competent jurisdiction to be illegal, invalid or void for any reason whatsoever, such provision shall be severed from the Rules and will not affect the legality, validity or enforceability of the remainder the Rules. Further, should any provision of the Rules be or become ineffective because of any change in applicable law, or should the Rules fail to include a provision that is required as a matter of the applicable law, the validity of the other provisions of the Rules shall not be affected thereby.

***24.***  ***<u>Definitions and Interpretation</u>*** 

In this Plan and in any Schedules to the Plan, unless otherwise required by the Rules:

24.1 <u>Definitions</u> 

**ADIs** means American depositary instruments being either American Depositary Shares or American Depositary Receipts of Novartis.

**Articles** means the articles of incorporation of the Company as amended from time to time.

**Base Salary** means the Participant's gross salary or the net salary where no gross salary has been defined, each excluding any overtime compensation, allowances, bonuses, commissions or premiums. The references to be used to determine the Base Salary may be specified in any applicable Schedules. This may include specific rules for the determination of Base Salary for hourly workers.

**Board** means the Company's Board of Directors or, to the extent permitted by applicable law, the Board's delegate(s), including but not limited to the Novartis Corporation P&O Solutions Board, or, following a Change of Control, those persons who comprised the Board immediately prior to such Change of Control.

**Canadian Participant** means a Canadian resident employee whose terms and conditions of employment are governed by Canadian local terms and conditions pursuant to a local employment contract with a Participating Group Company.

**Cessation of Employment** occurs, for the purposes of the Plan, when a Participant ceases to hold an office or employment with any Group Company provided that a Participant will not be treated as ceasing employment in circumstances in which that Participant is on a leave of absence where the Participant's right to re-employment is guaranteed either by statute or contract and employment is not otherwise terminated during such leave of absence (in which case the participant will cease employment at the time of such termination) and similar terms, such as "ceases employment" or "ceasing to be employed", shall be construed accordingly. For certainty, for the purposes of this Plan, the date upon which a Participant ceases to hold an office or employment with any Group Company shall be the actual date of cessation, whether such date is selected by the Participant, by mutual agreement between the Employing Group Company and the Participant, or unilaterally by the Employing Group Company, and shall not include any notice period or pay in lieu of notice period in excess of the minimum statutory notice period (if and as required by applicable employment standards legislation), whether or not such minimum statutory notice is actually given or pay in lieu of notice is given.

**Change of Control** shall have the meaning defined in the Novartis AG Employee Share Purchase Plan.

**Committee** means the Novartis Corporation Stock Committee.

**Company** means Novartis Corporation, a New York Corporation.

**Contribution Amount** means the elected amount of the Base Salary pay dedicated for purchasing Shares as documented in the Enrollment Request.

**Dividends** means all distributions in cash made to shareholders of the Company, as well as proceeds from sale of any rights allocated with respect to Shares such as subscription rights or partial rights or any other similar rights or entitlements.

**Election Period** means the period during which Eligible Employees elect the Contribution Amount, the Election Period typically lasts two to three weeks and precedes the Offer Period.

**Eligible Employee** means any employee of the Company or a Participating Group Company that is employed by the Company or a Participating Group Company and receives Base Salary during the Offer Period except for:

- employees whose customary employment is for less than five months,

employees who own Shares possessing 5% or more of the total combined voting power or value of all classes of stock of Novartis or of its parent or subsidiary corporation, and

- non-employee directors of Novartis Group

An Eligible Employee shall not include (and has not at any time included nor been intended to include) any individual during any period he or she is classified or treated by an Employing Group Company as an independent contractor, a consultant, or an employee of an employment, consulting, or temporary agency or any other entity other than an Employing Group Company, without regard to whether such individual is subsequently determined to have been, or is subsequently retroactively reclassified as, a common-law employee of the Employing Group Company during such period under applicable law.

**Employing Group Company** means the Participating Group Company by or in which the Participant is or, where the context so admits, was an office holder or employed.

**Enrollment Request** means the Participant's election of the Contribution Amount per pay period that shall be deducted from his or her net pay and withheld through payroll for the purchase of Shares.

**Group** means Novartis, all its direct and indirect subsidiaries and any other entity each determined by the Board to be a Group Company for the purposes of the Plan.

**Group Company** means any direct and indirect subsidiary of Novartis and any other entity each determined by the Board for the purposes of the Plan.

**Insider Restrictions** means restrictions on the dealing in Shares imposed by any law, regulation or Code of Practice (including the Novartis Global Insider Trading Policy, as amended or replaced from time to time) or otherwise.

**Market Value** at purchase shall be defined in relation to Shares:

(a) if
 the Shares are admitted to trading on the New York Stock Exchange (NYSE) an amount equal
 to the closing price on the Purchase Date;

(b) if
 the Shares are not admitted to trading on the New York Stock Exchange (NYSE) then such value
 as is determined by the Board.

**North America** means the United States of America, Canada and Puerto Rico.

**Novartis** means Novartis AG.

**Offer Period** means the period of three months during which the elected Contribution Amount is deducted per pay-period from the Participant's net Base Salary via payroll.

**Participant** means an Eligible Employee who submits a valid Enrollment Request.

**Participating Group Company** means a Group Company that is listed as a participating company by the Board. The Board shall identify Participating Group Companies as either "Section 423 Participating Group Companies" or as "Non-Section 423 Participating Group Companies." A Group Company must be a "subsidiary corporation" of Novartis AG, as defined in Code Section 424(f), in order to be a Section 423 Participating Group Company. For the avoidance of doubt, the Company shall be a Section 423 Participating Group Company.

**Plan** means the Novartis Corporation Employee Share Purchase Plan for North American Employees, as amended from time to time.

**Plan Administrator** means the third party engaged by the Company for support with the administration and technical execution of the Plan.

**Puerto Rican** means a Puerto Rican resident employee whose terms and conditions of employment are governed by Puerto Rican local terms and conditions pursuant to a local employment contract with a Participating Group Company.

**Purchase Date** means the last trading day of the respective Offer Period.

**Purchase Price** means the Market Value discounted by 15%.

**Rest of the World** means all countries where the Novartis AG Employee Share Purchase Plan is operated.

**Rules** mean the rules of the Plan (including all Schedules), as amended from time to time.

**Schedule** means a schedule to the Rules, as amended from time to time.

**Share** means an ADI of Novartis (New York Stock Exchange, Valor No. 567514, ISIN US66987V1098, symbol: NVS).

**Total Contribution Amount** means the total of Contribution Amounts per pay period accrued over the Offer Period.

**US Participant** means a United States resident employee whose terms and conditions of employment are governed by United States local terms and conditions pursuant to a local employment contract with a Participating Group Company.

**VegüV** means the Swiss ordinance in executive compensation and is the German abbreviation for the ordinance against excessive compensation in listed companies (in full "Verordnung gegen übermässige Vergütungen bei börsennotierten Aktiengesellschaften" or compensation of governing bodies in public companies such as members of the executive committee, the board of directors or the advisory boards).

24.2 <u>Interpretation</u> 

Unless the context requires otherwise: words importing the singular include the plural and vice versa; the masculine includes the feminine and vice versa; the word "includes" is not a word of limitation; references to "Schedule" shall refer to the appropriate Schedule to the Plan; headings and boldings are for convenience only and do not affect the interpretation of these Rules.